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Abstract
Rheumatoid arthritis is a chronic, systemic inflammatory disease, with certain 
evidence of multiple factors involved, but also with the strong autoimmune compo-
nent, leading to a high potential for disability, through synovial inflammation and 
joint destruction. Diagnostic methods and management possibilities have recently 
improved, thus leading to a better outcome, based on the treat to target recom-
mendation. Although biologic agents represent efficient therapeutic agents, in the 
last few years, the advances in understanding the mediators involved in rheumatoid 
arthritis pathogenesis have provided new targeted therapies, represented by small 
molecule inhibitors against the Janus kinases that contribute in the signaling path-
ways of various cytokine receptors.
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1. Introduction
Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic disease that tar-
gets primarily the synovial joint lining and causes progressive disability. Untreated, 
PR leads to the destruction of the joints by the erosion of cartilage and bone mate-
rial. Loss of physical function is the aftermath, which is why early treatment is vital 
for controlling disease activity and for preventing joint damage.
Angiogenesis is an important process for the growth and development of all 
tissues, during which new blood vessels are formed from pre-existing vascu-
larization and play a critical role in the pathogenesis of several inflammatory 
autoimmune diseases, such as PR. Angiogenesis is triggered by the dominance of 
pro-angiogenic factors over endogenous angiostatic mediators. Studies conducted 
over the past two decades have suggested the involvement of numerous pro-
angiogenic factors such as metabolites, ions, growth factors, hypoxia-inducible 
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factors, cytokines, chemokines, extracellular matrix metalloproteinases, and 
adhesion molecules, in RA pathogenesis.
Also, these pro-angiogenic factors were targets for possible therapies. Thus, the 
research has led to the emergence of new therapies with a key role in modulating the 
activity of the cellular immune response and inflammation in the synovial tissue.
According to studies, patients with RA, after treatment with biological agents, 
showed a significant decrease compared to the initial levels of acute-phase reactants 
and inflammatory proteins: C-reactive protein (CRP), the red blood cells sedi-
mentation rate (ESR), pro-inflammatory cytokines (tumor necrosis factor-alpha, 
TNF-α; interleukins, IL-17, IL-8, IL-18), chemokines (CXCL12), growth factors 
(angiopoietins, Ang-1, Ang-2; growth factor of vascular endothelium, VEGF), 
adhesion molecules (vascular adhesion molecule 1, VCAM-1) and matrix metal-
loproteinases (MMP-9 and MMP-13).
Biological therapy has brought many benefits for patients, by improving the 
prognosis, evolution, stopping or reducing destructive lesions, obtaining remission 
and thus increasing the quality of life and maintaining social integration.
Biological therapy is no longer reserved only for cases that do not respond to 
classical therapy, as clinical studies have shown that the number of swollen and 
painful joints decreases, as well as the rate of osteoarticular destructive lesions.
2. Rheumatoid arthritis: pathogenesis
The pathological mechanisms that drive the synovial inflammation and struc-
tural damage in RA are complex.
Research in the field of RA pathogenesis has been an essential tool in the devel-
opment of disease-modifying drugs, biologic therapy, and the more recent targeted 
therapy. There are separate domains of research that combine to offer a complete 
picture of the disease etiopathogenesis. These include the study of trigger agents, 
autoantigen-autoantibody interaction, genetic susceptibility, articular and extraar-
ticular pathology. Major disease subtypes defined by anti-citrulline peptide anti-
body (ACPA) positivity provide some differences in genetic associations, immune 
response, disease severity and treatment effectiveness [1].
The presence of ACPA is highly specific for RA [2] and occurs in response to a 
set of citrullinated proteins, such as fibrin, fibronectin, vimentin, type II collagen 
and histones [3]. Citrullination is catalyzed by peptidylarginine-deiminase (PAD), 
a calcium-dependent enzyme. Another post-translational process that drives the 
formation of autoantigen in RA is carbamylation. It is defined by the change of 
the amino acid lysine to homocitrulline. Smoking and chronic inflammation, both 
characteristic features in the context of RA pathogenesis, are thought to enhance 
the process of carbamylation [4].
A series of environmental factors, such as cigarette smoking and silica have been 
associated with RA development. Smoking has provided some strong evidence of 
the potential to generate citrullinated proteins. In a historical Danish twin cohort 
study, Svendsen et al. concluded that 20 years of smoking doubles the risk of RA 
development [5]. Environmental factors can generate an epigenetic regulation and 
influence specific RA immune reactions to citrullinated proteins [6]. Exposure to 
smoke, silica or carbon-derived nanomaterials can activate antigen-presenting cells 
and PADs by triggering mucosal toll-like receptors.
Pathogenic infections associated with the onset of rheumatoid arthritis can 
lead to a faulty immunological tolerance towards essential self-antigens. This can 
subsequently cause chronic joint inflammation along with an imbalance between 
the various T helper subsets [7].
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Among the infectious agents regarded as potential triggering factors, 
Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans are of particu-
lar interest. Studies on both microorganisms have linked periodontal infection to 
RA autoimmunity. P. gingivalis is constitutively equipped with the PAD enzyme [8]. 
The presence of P. gingivalis has been linked to both autoantigen release and ACPA 
production [3]. Periodontal space and lungs are thus considered potential triggering 
sites for RA. The role of Epstein–Barr virus (EBV), cytomegalovirus and parvovirus 
B19 (B19) are controversial. Sherina et al. conclude in a 2017 study that high anti-
viral antibody levels for EBV and B19 may, in fact, have a protective role against 
ACPA-positive RA [9].
When highlighting the etiopathogenesis of RA, certain species of Collinsella are 
involved by establishing an increase in gut permeability, a decrease in the activity of 
tight junction proteins and by way of regulating the synthesis of IL-17A at the level 
of the epithelium. More broadly, gut dysbiosis has been implicated in the patho-
genesis of RA through the recruitment of essential inflammatory mediators such as 
TNF-alfa, IL-6, and IL-17A [10]. One metagenome-wide association study recently 
revealed a link between RA and multiple species belonging to the genus Prevotella, 
such as Prevotella denticola [11].
There has not been thus far sufficient evidence to advocate for a clinical correla-
tion between an infection with Helicobacter pylori (H. pylori) and RA, despite the 
results of experiments performed in vitro, which have revealed that chronic stimu-
lation of B lymphocytes with the urease made by the H. pylori leads to an increased 
production of autoantibodies, specifically rheumatoid factor (RF), an immuno-
globulin M (IgM) antibody directed to the Fc portion of IgG. While RA patients are 
at risk of developing peptic ulcers, it is unclear whether this is due to an increased 
prevalence of H. pylori infection or because of the ample use of anti-inflammatory, 
non-steroidal medication [12].
It is known that viruses can modify the clinical picture depending on genetic 
background, immune responses elicited by the host and the type of virus strain 
involved. Certain viruses such as parainfluenza have been associated with a higher 
incidence of RA in men, and more broadly with both male and female patients 
below the age of 40 [13].
There is an overall agreement that pathogenesis in RA is linked with genetic 
susceptibility. Studies have found more than 100 susceptibility loci in RA patients 
[14]. Twin studies in which heritability is reported to be ~60% provides strong 
evidence for this matter. It is also speculated that the interplay between environ-
mental factors and genetics may, in fact, lay the foreground for the specific autoim-
mune reactions and further transition to the joint disease stage. A major genetic 
risk factor associated with RA concerns the human leucocyte antigen (HLA) class 
II region. The conserved amino acid sequence located at the antigen-binding site of 
the antigen-presenting molecule, encoded by the alleles of HLA-DRB1 is referred to 
as the shared epitope (SE) [14]. The strongest genetic associations in RA are identi-
fied in the HLA-DR1 and HLA-DR4 serotypes. Some studies do not link the HLA II 
locus to ACPA response directly [15, 16], rather to the progression from ACPA(+) 
to ACPA(+) RA, through a process of maturation via T cells which activate ACPA-
producing B-cells. It is assumed that SEs play an important role in the antigen 
presentation process. Thus the different alleles at the SE level can influence the 
interaction between HLA class-II and the specific receptor of T lymphocytes (TCR) 
or between HLA class-II and antigen. Studies on SE phenotypes and specific HLA-
DRB1 subtypes revealed that HLA-DRB1*04 has a significantly higher frequency in 
RA and is associated with seropositivity independent of the smoking status [17, 18].
ACPA(+) and ACPA(−) RA patients have similar hereditability, reported 
at 68% and 66%, respectively. The two serotypes display differences in genetic 
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susceptibility, including a significantly lower SE contribution in the seronegative 
disease of 2.4%, compared to 18% in ACPA(+) RA [19]. A major genetic risk factor 
outside the HLA region concerns the protein tyrosine phosphatase non-receptor 22 
(PTPN22) gene [14]. Other non-HLA susceptibility genes identified in both disease 
subgroups include TNFAIP3, GIN1/C5orf30, STAT4, ANKRD55/IL6ST, BLK [14]. 
The protective role of specific HLA-DRB1 alleles has been reported in one meta-
analysis, in which HLA-DRB1*13 accounted for a lower risk of ACPA-positive RA 
[20]. Studies on the outcome of patients with undifferentiated arthritis determined 
several susceptibility loci (PTPN22, TRAF1/C5, AFF3, KIF5A, TAGAP) related to 
disease severity [21]. These genetic loci may provide a tipping point in the disease 
progression and identify as prognosis markers for the transition to an established 
RA [14].
Autoantibody secretion generated by the autoantigen release can precede the 
onset of fulminant joint disease by several years [22]. High-titer RF is of high 
diagnostic and prognostic value and is linked to erosive RA. ACPA is the most 
specific marker antibodies for RA and is linked, similarly to RF with erosive disease. 
Another autoantigen with potential pathogenetic relevance is the heterogeneous 
nuclear ribonucleoprotein-A2 (RA33) which is targeted by autoreactive T cells [2].
Both the innate and adaptive immune systems contribute to initial antibody 
production and further development of sustained chronic synovitis. The fibroblast-
like synoviocytes interact with cells of the innate immune system which include 
macrophages, monocytes, mast cells, and dendritic cells. ACPA target citrullinated 
proteins on the surface of macrophages and monocytes, which in turn enhances 
the production of pro-inflammatory mediators [3]. Activated mast cells have an 
essential contribution to the pro-inflammatory milieu through IL-17 A secretion 
[23]. The involvement of the adaptive immune response is based on the antigen 
activation of major histocompatibility complex (MHC) class II dependent on T cells 
(cell-mediated immunity), cytokine release, and stimulation of B-cell antibody 
production (humoral immunity).
The exact relationship between reported antibodies relating to the disease and 
the pathogenic features observed remains a mystery due to lack of research. Limited 
data thus far comparing RA serotypes indicate different underlying processes that 
can drive parallel pathways towards similar clinical phenotypes. There is evidence 
of T-cell-mediated immune dysregulation in RA irrespective of autoantibody pro-
duction [24]. Serotype distinctions include differences in immune cells subtypes, 
cytokines and chemokines [25].
The synovium in patients with established RA displays an inflammatory infil-
trate composed of a heterogeneous set of immune cells. Neutrophils present in the 
synovial fluid have an extended lifespan and feature an enhanced production of 
reactive oxygen species and neutrophil extracellular traps (NETosis) [25]. Synovial 
T cells, especially CD28-CD4+ T cells are autoreactive, produce interferon-gamma 
(IFN-γ) and are resistant to apoptosis [26]. Differentiated effector T cells, helper 
types (Th1, Th2, Th17) contribute to cytokine secretion. Antigen-specific T cells 
or T cells activated by the pro-inflammatory milieu of the synovia are capable of 
stimulating monokine production by monocytes and macrophage-like synovio-
cytes, especially interleukins (IL-1, IL-6) and TNF-α [26]. The T-cell dependent 
IL-17 cytokine has a significant pathogenic role by inducing cartilage degrada-
tion and bone erosion through stimulation of receptor activator of NF-κB ligand 
expression on osteoblasts. The Th17 cells population is increased both in joints 
and peripheral blood of patients with RA [27]. IL-23 produced by dendritic cells 
promotes the survival and expansion of Th17 cells. It is thought that an imbalance 
between IL-12 (Th17 inhibitor) and IL-23 secretion by dendritic cells contributes to 
RA pathogenesis [26].
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Various chemokines, cytokines, growth factors, and cell adhesion molecules 
promote neovascularization in the setting of chronic inflammation. In RA, there 
is an abundance of angiogenic factors, of which VEGF is of major importance. 
Inflammatory cytokines, such as TNF-α, IL-1, IL-6, IL-17, IL-18, granulocyte 
and granulocyte-macrophage colony-stimulating factors (GM-CSF), may also 
induce angiogenesis through VEGF-dependent pathway [28, 29]. Affected 
patients have been shown to have high levels of VEGF and significantly lower 
levels of IL-35 [30, 31].
The inflammatory cascade and synovial neoangiogenesis drive specific struc-
tural changes related to RA pathology. Synovial hypertrophy is related to abnormal 
proliferation of dysfunctional fibroblast-like synoviocytes (FLS), resistant to 
apoptosis. FLS sustain joint damage by the secretion of MMPs and tissue inhibitors 
of metalloproteinases. Cartilage damage is induced by the action of MMPs which 
cause disassembly of the type II collagen network. Also, chondrocyte apoptosis is 
enhanced by cytokine, mainly IL-1 and IL-17A. Inflammatory cytokines promote 
bone erosion through pro-osteoclastogenic effects. Also, osteoclast differentiation 
may be induced via immune complexes and antigen-binding of ACPA on osteoclast 
precursors. Bone erosions are usually located at the site where the joint capsule 
inserts on the periosteum [32, 33].
3. Rheumatoid arthritis: clinical aspects
3.1 Clinical picture of early arthritis
One of the most important things to remember about RA is that it should be 
diagnosed as early as possible. This is of paramount importance since rheumatoid 
arthritis is a disease characterized by structural bone lesions that lead to bone 
deformity and functional disability. However, trying to make an early diagnosis of 
this disease can prove to be extremely difficult sometimes, and that is because there 
is no specific or particular symptom or sign of either early or very early RA (eRA).
Moreover, the 2010 European League Against Rheumatism/American College of 
Rheumatology (EULAR/ACR) classification criteria for RA, which tries to capture 
patients as early as possible, is to be applied ONLY to people having at least one 
joint with CLINICAL SYNOVITIS [34]. But, even when synovitis is present, it is not 
always the expression of early RA.
While early signs and symptoms of RA can be mimicked by other diseases, there 
are some which should be taken into consideration, such as fatigue, minimal joint 
pain, joint warmth, joint stiffness, limping, reduction of range of motion, fever, 
anemia, and depression. It is easy to see that all these are not at all specific, not even 
for full blown rheumatoid arthritis and even less so for early/very eRA [35].
The interest of knowing how to interpret symptoms in eRA derives from mul-
tiple reasons, one of the most important being that it would be extremely useful (on 
a personal, as well as a societal level) to be able to predict, based on the symptoms 
of people, who will develop RA and who will not. Unfortunately, with the knowl-
edge we have today, this is not yet feasible. There are still too few studies designed 
especially for assessing symptoms during this initial period of the disease [36].
Nevertheless, if one tries to group the symptoms which may appear during the 
early stages of RA, one can delineate three categories [37]:
a. Non-specific symptoms: which are in fact, general (systemic) symptoms 
produced through the intervention of pro-inflammatory cytokines, which may, 
thus, intervene in any inflammatory disease, articular or not. Among them, we 
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can outline fatigue, a general feeling of being “un-wellbeing,” anxiety, depres-
sion, non-specific myalgia or sharp/dull pain near the joints but not in the 
joints. Sometimes there is low-grade unexplained fever and, rather frequently, 
sleep disturbances which worsen the general feeling of being “un-wellbeing.” 
To take just one example, fatigue, which is a very common and, frequently, 
overlooked symptom in RA, correlates with active disease in the sense that it 
is more pronounced when the disease activity is higher. Its origin is not well 
understood; it may be the response of the organism to the presence of chronic 
inflammation, mediated by the action of IL-6. Poor sleep and anemia can 
contribute to fatigue in RA. This symptom can affect relationships, emotions, 
mood, productivity, creativity, the general feeling of happiness. Fatigue from 
RA can associate with poor appetite and weight loss [35].
All these non-specific symptoms may appear in variable proportions in people 
affected by eRA and their importance resides in the significance pertaining to 
the risk of a person presenting these symptoms, to develop established RA.
b. Symptoms related to the joints; may vary from mild joint stiffness (sometimes, 
without having the so-called characteristics of inflammatory joint stiffness) 
to non-explicable, non-specific joint pain, usually of short duration, with no 
local signs of inflammation of the joint. As one can see, these are also totally 
unspecific to the possibility of later developing RA; which is why their pres-
ence should prompt a very careful evaluation. On the other hand, when people 
complain of joint pain, diagnosing them might be easier as pain can motivate 
people to see a doctor.
c. Symptoms related to functional capacity. These symptoms interfere with one’s 
ability to perform daily living activities. For instance, when one is not capable 
of performing the opposing movement of the thumb, and hence, not able to 
make a fist, one will not be able to open a jar’s lid. Likewise, if the symptoms 
are located in the lower limbs, one might not be able to walk or wear shoes. 
As can be ascertained, these are elements of functional disability that one can 
encounter in the established RA patient, as well as in other diseases. Therefore, 
as these are also non-specific to the early phase of RA, they should also be 
evaluated with care, to reach a correct diagnosis, more so a therapeutic one.
Regardless of the category of symptoms an individual has, the interpretation 
of their significance is much more difficult and doctors would like to be able to 
have some hints as to WHAT should he investigate in order not to miss the right 
diagnosis, in the given window of opportunity. Investigations should be primarily 
directed to populations or subjects at high risk including female gender, smoking, 
alcohol, obesity, unhealthy dietary intake, having a family member diagnosed with 
RA, presence of ACPA, poor dental health, low socioeconomic status. As such, 
people having symptoms of the above and also one or more of the mentioned risk 
factors should be given the most attention in assessing their presenting health 
condition [38].
One other method used to evaluate symptoms of eRA is to, retrospectively, 
question patients with established RA about their original symptoms [39], followed 
by making appropriate questionnaires, which are to be used prospectively, to make 
an early diagnosis. Such an analysis of the literature on this topic was made by Stack 
et al. and, reviewing 26 papers concentrating on the way patients diagnosed with 
RA reported their initial symptoms, they found 5 “themes” that describe patient’s 
initial complaints [39].
7Diagnostic Challenges and Management Update in Rheumatoid Arthritis
DOI: http://dx.doi.org/10.5772/intechopen.91965
The first is concerning the swelling of the joint. It was often described as being 
severe and was most frequently localized at the hands and feet [40–42]. It also 
has an impact on the ability to perform activities of daily living [43, 44]. Patients 
reported that it was a progressive feature [45, 46] and that it was sometimes associ-
ated with some degree of joint pain [47, 48]. These findings suggest that it might be 
rational to closely monitor a person complaining of recent onset sensation of joint 
swelling, even if the swelling itself is not apparent to the doctor.
The second theme used by established RA patients to retrospectively describe 
their initial symptoms is one of pain and local sensibility, with multiple localiza-
tions, again, more frequently, on the hands and feet [49–52] and rarely on the 
shoulders and hips. Two rather descriptive patterns were identified:
a. gradual occurrence of pain: the most often used descriptors were “episodic 
pain,” “gradual pain,” “easy pain,” “vague pain.” The interpretation given by 
patients was usually taking into account the activities performed during the 
day, therefore not much attention was given to the pain until it became persis-
tent and higher in intensity [53–55];
b. acute onset of pain: the most often used descriptors in this circumstance, were 
“severe pain,” “resistant pain,” “disability provoking pain,” “unbearable pain.” 
Some of the patients describe the occurrence of pain like an “on-off switch” 
phenomenon. Most often, this pattern was rapidly followed by the occurrence 
of other symptoms, as well. As such, this kind of joint pain is the one that will 
get the patient to visit the doctor much faster [45, 46, 55].
The third theme of patients’ symptoms is joint stiffness. Quite surprisingly, this 
was very briefly mentioned and patients never gave a full description, neither was 
any emphasis put on the significance of the term [46]. In some instances, it was 
associated with other symptoms, such as fatigue and swelling of the joint [55].
The fourth theme reported retrospectively by patients with established RA, 
to describe their initial symptoms, is fatigue and muscular weakness [56]. Some 
patients have reported this as the impossibility to “lift my food tray” [57] or to “lift 
my toddler” [43]. It appears that fatigue is a really important feature of the begin-
ning of eRA [56]. Some patients even described a “flu-like” sensation of muscular 
weakness all over their bodies [58].
The fifth and last theme that patients referred to when remembering their initial 
symptoms of RA is the emotional impact of prolonged suffering [55, 59–61]. It is 
easily conceivable that a state of sustained discomfort in which the patient does 
not know for how long it will last and how it may evolve will produce emotional 
distress. Due to this, patients reported feelings of fear, anger, anxiety, uncertainty, 
ambivalence. For some patients, this emotional impact was so strong that they had 
depression and even suicidal ideation [59]. When the emotional disturbance is 
significant, finding a diagnosis, even that of established RA, comes as a relief [60].
These five themes revealed by Stack et al. are useful for daily clinical practice 
due to the fact that they can point out of the mass of patients that a physician sees 
every day, those that the physician should actively follow closely, in order to be able 
to make the right diagnosis of (preferably) eRA, if this should be the case [39].
Since RA is a systemic disease, potentially affecting any organ system in the 
body, in the proper context, some of the extraarticular manifestations of the 
disease, can point out the necessity to further search for a correct diagnosis. Of 
the numerous such manifestations, one should perhaps remember the following, as 
a possible manifestation of eRA: peripheral nerve entrapment (e.g. carpal tunnel 
syndrome), “idiopathic” pulmonary fibrosis or nodules, unexplained amyloidosis, 
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cardiac nodules of unknown origin, cutaneous nodules (that can and should prob-
ably be biopsied when unexplained), “idiopathic” vasculitis [38].
As we know, in 2014, Zhao et al. developed classification criteria for eRA, which 
take into account both clinical and biological aspects of the disease and perform at a 
variable but acceptable specificity and sensitivity [62, 63]. Nevertheless, they imply 
that the presence of clinically evident arthritis; and this is, sometimes, not eRA, 
since everybody tries to make the diagnosis as early as possible! Therefore, these 
criteria are useful but will miss some of the early or very early RA cases.
One must not forget that we also have the EULAR recommendations on treat-
ment of eRA [64], which state, as one of the overarching principles that “A definitive 
diagnosis in a patient with early arthritis should only be made after a careful history 
taking and clinical examination, which should also guide laboratory testing and 
additional procedures,” while in the recommendations it is mentioned that “Clinical 
examination is the method of choice for detecting arthritis” and that “if a definite 
diagnosis cannot be reached and the patient has early undifferentiated arthritis, risk 
factors for persistent and/or erosive disease, including number of swollen joints, 
acute phase reactants, rheumatoid factor, ACPA and imaging findings, should be 
considered in management decisions. Patients at risk of persistent arthritis should be 
started on DMARDs as early as possible (ideally, within 3 months), even if they do 
not fulfill classification criteria for an inflammatory rheumatological disease.” Thus, 
EULAR provides us with some guidance as to how to attempt to make a diagnosis as 
early as possible, as well as following it swiftly with the correct management [64].
Identifying (especially) seronegative future established RA patients in the earli-
est stage of their disease is a difficult endeavor. Until now, we do not know for cer-
tain if the symptoms of a person are, by themselves, enough to efficiently stratify 
the risk of a person to develop established RA [65]. And this is an important unmet 
need in the field of RA, which precludes continuous study to lower the pressure 
on the healthcare system, by preventing the major, often irreversible, disabilities 
associated with this disease, through better early diagnostic expertise.
3.2 Established rheumatoid arthritis
Joint pain is the universal characteristic in RA patients, but the long-standing 
disease has several features, easily recognizable by a trained rheumatologist, but 
often misdiagnosed by other specialists. The key to the recognition of the clini-
cal and physical findings of RA is the capability to recognize the outcome of the 
synovial proliferation and inflammation [66]. As was already stated before, RA can 
affect any peripheral joints, with predilection on the small joints of the hands and 
feet, followed by the elbow, shoulder, ankle or knee.
3.2.1 Hand and wrist
Hand and wrist involvement with secondary deformity is a typical feature of 
late RA [67, 68]. If in the eRA, the physical findings are not extensive, in the late 
disease one can identify an entire panel of changes. The late, irreversible and most 
prevalent changes in hands include “swan-neck” and “boutonnière” deformities, 
along with metacarpophalangeal joints (MCP) swelling, subluxation and “ulnar 
drift,” or ulnar deviation (Figure 1). Swelling of the MCP and wrists joints, together 
with atrophy of the intrinsic muscles of the hand, leads to the aspect of the hand 
like “two-humped camel’s back,” while the ulnar deviation makes it similar to 
the “mole’s paw.” Persistent inflammation adjacent to ulnar styloid, together with 
the laxity of the radioulnar ligament leads to a movement of the styloid under the 
examiner’s pressure, similar to the “piano key” [68].
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The boutonnière deformity presumes the flexion of the proximal interphalangeal 
(PIP) joint and extension of the distal interphalangeal (DIP) joint [69], whereas the 
swan-neck, by contrast, means hyperextension of the PIP and flexion of the DIP [68, 
70]. The cause of the boutonnière deformity is the lesion of the central slip of the 
extensor tendon, secondary to tenosynovitis and PIP swelling, with the lateral and 
volar displacement and conversion of the lateral bands of the extensor tendon, into 
flexors of the PIP joint. In time, shortening of the tendon leads to hyperextension 
of the DIP joints. If the DIP swelling is disrupting the extensor tendons, the joints 
will be forced to remain flexed (due to the action of the only remaining tendons, 
the flexors). Besides, if the bulging of the PIP is volar, the lateral bands subluxate 
dorsally, generating hyperextension in the PIP joint and the aspect of the swan-neck 
deformity.
The involvement of the thumb results in severe functional impairment, due to 
the loss of the grip between the index finger and the tip of the thumb. The most 
prevalent pathological aspect of the thumb in RA is one of a “flails,” followed by the 
boutonnière deformity, which is the same as described before, just one joint back 
proximally [66].
Extensor tenosynovitis might lead to tendon ruptures, especially at the level 
of the 6th compartment of extensors, while flexor tendon involvement includes 
besides thickening of the tendon sheet that could generate either “trigger finger” or 
a carpal tunnel syndrome [66].
It is not uncommon that the same hand develops different deformities simulta-
neously leading to a major impact on hand function and subsequently on the ability 
to perform daily life activities [70].
Figure 1. 
Images of the small joints of the hands and feet, showing boutonnière - arrow (A and C), swan-neck – Empty 
arrow (B and C) and hammer toes deformities – arrowhead (D).
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3.2.2 The elbow
The elbow is often involved both early and in longstanding rheumatoid arthritis. 
Because of its unique role in maneuvering and positioning the hand in space, the 
loss of normal motion and stability, or increased pain with the use of this joint are 
all significant sources of impairment in patients with RA [71]. Synovitis of the 
elbow joint can be identified by palpation between the olecranon and the epicon-
dyles, especially the lateral one. Olecranon bursitis is a common finding in patients 
with RA but should be differentiated from the one appearing in polyarticular gout. 
To mention, in RA it tends to be more frequently bilateral [66].
3.2.3 The shoulder involvement
The shoulder joint is a complex joint and because of its deep location it is 
difficult to confirm accurately the joint effusion, or the rotator cuff tears only by 
physical examination, therefore shoulder lesions are often under diagnosed [72]. 
When involved, it might generate limitation of motion in all planes, with suggestive 
secondary scapulothoracic movement, or “shoulder pad” sign. The pain generated 
by joint effusion, subacromial subdeltoid bursitis, or rotator cuff tendon tears is 
often referred into the deltoid muscle. The fluid inside the biceps tendon sheet is 
not uncommon [72].
3.2.4 The knee joints
Knee joint synovitis is a frequent finding in patients with RA, anterior swelling 
being easily detectable through clinical examination, by the “bulge sign” or the bal-
lottement of the patella with the index finger downwards, into the fluid. The Baker 
cyst is a benign fluctuant swelling of the gastrocnemius-semimembranosus bursa in 
the popliteal fossa at the back of the knee [73], resulted after severe effusion at the 
level of the knee joint. Hip joint involvement is associated with pain over the greater 
trochanter, probably due to bursitis and pain elicited by Patrick’s test, or Flexion-
Abduction-External Rotation maneuver (FABER) [74].
3.2.5 The ankle involvement
The ankle is an important weight-bearing joint, with a lot of structures involved 
in RA. Synovitis is common at the level of the tibiotalar subtalar and talonavicular 
joints, with a high impact on the patient’s quality of life [75]. Tenosynovitis of 
the medial or lateral compartments is increasing the functional impairment. The 
forefoot comes with specific changes, including calluses under the metatarsal heads 
and secondary ulcerations, or joint deformities leading to the “hammertoes” aspect 
(Figure 1), resembling the piano hammer [66].
3.2.6 Other types of involvement
Bilateral pain, tenderness, swelling and limitation of jaw movements might be 
the result of temporomandibular joint involvement and due to these symptoms, 
patients experience limitations in their daily activities, such as eating, speaking and 
swallowing.
The involvement of the cervical spine is the most serious skeletal manifestation 
in patients with RA. Instabilities of the upper cervical spine can lead to headache, 
neck pain, paresthesias, weakness, signs of vertebrobasilar insufficiency or neuro-
logical complications such as bowel and bladder sphincter impairment [66].
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3.2.7 Extraarticular features of RA
Most frequent extraarticular features of RA are represented by the rheumatoid 
nodules, with subcutaneous disposition on the extensor surfaces and joints at sites 
of chronic mechanical irritation and typical clinical characteristics [76, 77]. The 
diagnosis requires sometimes biopsy to differentiate them from gouty tophi but 
need no specific treatment unless they are causing pain, interference in mechanical 
function, nerve compression, or other important local phenomena. It is uncom-
mon to find nodules within the first year from the disease onset, whereas it is more 
like a longstanding disease feature. To note, that patients with rheumatoid nodules 
are at an increased risk of developing other severe extraarticular manifestation. 
Association of HLA-DRB1*04 gene and smoking were found to be important 
predictors for the extraarticular disease [77].
Hematological abnormalities are not uncommon, especially anemia of different 
causes, such as chronic inflammatory disease, through hepcidin intervention and 
blockage of iron inside macrophages, or secondary to the gastrointestinal complica-
tion of the anti-inflammatory treatment or loss of folic acid during methotrexate 
therapy. Thrombocytopenia is uncommon, usually drug-induced. More frequently, 
RA patients manifest thrombocytosis of unknown cause, but correlated with dis-
ease activity and involved joint count. Lymphadenopathy is frequent in active RA, 
with a benign histological pattern, usually located in axillary, inguinal or epitroch-
lear areas. The lymph nodes are usually not painful and mobile [76].
Felty’s syndrome represents the association of RA with splenomegaly and leuko-
penia (neutropenia) and usually occurs in seropositive patients with longstanding, 
deforming disease with rheumatoid nodules present. Some of those patients may 
also present thrombocytopenia and extremity ulcerations (lower leg) and hyper-
pigmentation of the skin, and are positive for antinuclear antibodies. To mention an 
increased risk of opportunistic infections, due to neutropenia [78].
Hepatic involvement is non-specific and minimal, related mostly to treat adverse 
effects, with an increase of liver enzymes that should decrease with discontinuation 
of the incriminated drug. On the other hand, in up to 65% of patients with Felty’s 
syndrome, there are liver abnormalities, from portal fibrosis and abnormal lobular 
architecture to nodular regenerative hyperplasia [77, 78].
Pulmonary complications of RA are frequent, with men being more often affected 
than women and include pleural disease, in up to 50% in autopsies studies, paren-
chymal peripheral pulmonary asymptomatic nodules (PPP nodules), that can 
measure up to 8 cm in diameter, diffuse interstitial pulmonary fibrosis, or bronchi-
olitis obliterans organizing pneumonia (BOOP). Pulmonary nodules and pneumo-
coniosis appear in patients with RA and extensive exposure to coal dust (Caplan’s 
syndrome), silica and asbestos. The RA- associated interstitial pneumonitis should 
be distinguished from the one generated by the methotrexate toxicity, the last one 
usually having a subacute onset, with low radiographic evidence of fibrosis, but 
rapid symptom progression. Inflammation of the cricoarytenoid joint might lead to 
other respiratory complications – upper airways obstruction [76, 79].
Heart disease presumes all cardiac structures involvement by intricate complex 
mechanisms of nodule formation, vasculitis of the coronary arteries, amyloidosis, 
serositis, valvulitis or fibrosis. Pericarditis is the most common cardiac feature of 
heart involvement, usually asymptomatic [80, 81]. Myocardial disease secondary 
to granulomatous lesions similar to rheumatoid nodules can lead to arrhythmia. 
Valvular granulomatous lesions might generate dysfunctionalities at the level of the 
mitral and aortic valves.
Rheumatoid vasculitis is a panarteritis, with mononuclear cells infiltrate and 
fibrinoid necrosis, which leads to clinical manifestations such as peripheral 
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neuropathy, palpable purpura or visceral infarcts. It is frequently associated with 
increased RF, erosive disease and rheumatoid nodules [80].
Other extraarticular manifestations of RA include neurological impairment, second-
ary to mononeuritis multiplex, to nerve compression by synovial proliferation (carpal 
tunnel syndrome) or to atlantoaxial subluxation; eye involvement includes keratocon-
junctivitis sicca, episcleritis or scleromalacia perforans (secondary to a perforating 
rheumatoid nodule). Glucocorticoids might cause glaucoma and cataracts and chlo-
roquine derivates cause retinopathy; the gastrointestinal disease can be secondary to 
mesenteric or hepatic vasculitis or associated with anti-inflammatory treatment [77].
Amyloidosis might complicate RA in up to 0.7% of patients with longstanding 
disease, leading to a poor outcome, with only 58% survival rates at 4 years [76].
Bone involvement is also frequent in rheumatoid arthritis patients, secondary 
to osteoclastic hyperactivity and or osteoblastic hypoactivity, in patients with 
impaired moving, local effect of proinflammatory cytokines or to the adverse effect 
of glucocorticoids [82].
Muscle atrophy is frequent, especially near affected joints. Inflammatory myositis 
or glucocorticoid myopathy (usually with the use of higher doses) might be present 
in patients with RA [76, 77].
4. Rheumatoid arthritis: imaging
Recent advances in the imaging field and therapeutic possibilities are changing 
the outcome in RA. Still, conventional radiology (CR) represents the main imaging 
method for rheumatoid arthritis patients’ evaluation, in daily practice. The treat to 
target approach has brought into attention the new methods, ultrasonography (US) 
and magnetic resonance imaging (MRI), as more sensitive and specific imaging 
modalities. In this way, CR remains a method for identifying old and late changes, 
lesions that already happened, while US and MRI are the methods for identifying 
acute inflammatory lesions and details of small structural changes. Other methods, 
such as arthrography, computer tomography (CT) or scintigraphy remain suitable 
for complex cases and will not be subject to our paper [77].
Conventional radiology, a cheap and widely available method shows a wide 
spectrum of changes at the level of the peripheral joints, including hands, wrists, 
feet, and ankles or even larger joints (knee, shoulder, elbow), depending on the dis-
ease duration. Thus, imaging of any joint disorder, including rheumatoid arthritis 
should start with this method [77].
Peripheral joint involvement shows typical radiographic changes in rheumatoid 
arthritis including soft tissue swelling related to joint effusion or synovitis, juxta-
articular osteoporosis, joint space narrowing and the late disease changes, bone 
erosions, and ankylosis. To note, the fact that joint space narrowing (JSN) is a good 
indicator for hyaline cartilage loss, as the articular space is mainly composed of the 
two-cartilage thickness sum, normally about 2 mm [83]. A comparison with adja-
cent or contralateral joints might clarify narrowing. Erosions occur earliest at the 
level of the carpal bones, especially pisiform or triquetrum, at the level of the ulnar 
styloid and second metacarpophalangeal (MCP) joint, in the bare area (metacarpal 
head, with no cartilage) [84]. Studies showed that up to 30% of the patients do not 
develop erosions in the first 2 years from disease onset, but still, most of the patients 
do, a fact that led to the expert recommendation of repeating CR every 6–12 months 
in eRA and every 1–2 years in late disease [85].
To quantify lesions and for a better follow-up of the disease, Sharp proposed a 
scoring system of erosions and JSN of hands [86]. The modified Sharp score, proposed 
by Van der Heijde, included feet, for a total of 16 areas evaluated for erosions and 15 for 
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JSN in each hand and 6 areas for erosions and six for JSN in each foot [87]. Radiographic 
progression can redefine remission, as clinically quiet joints often progress.
CR of the spine might show some abnormalities, especially in the cervical seg-
ment, which is involved in more than half of the patient [85]. The most frequent 
finding in this area is atlantoaxial subluxation and basilar invagination [88, 89], both 
identified best in a lateral radiograph, with the flexed neck. For the diagnosis of atlan-
toaxial subluxation, one should measure the distance between the anterior arch of C1 
and anterior aspect of the dens of C2. Expected values in normal subjects should not 
exceed 3 mm in adults and 5 mm in children. The distance higher than those cutoffs 
lead to a diagnosis of subluxation and the ones higher than 8 mm require surgical 
intervention. Basilar invagination diagnosis should be confirmed by MRI or CT [88].
US was recently included by EULAR recommendations on the use of imaging, 
between the techniques with a potential role in RA diagnosis and management 
[90, 91]. The reflection of ultrasound waves by body structures generates US images 
of those structures in the greyscale (GS) [92]. Adding the Doppler technique to the 
examination, we obtain information on the blood flow inside structures. The higher 
the ultrasound frequency, the higher the detail on the image, but lower penetrance. 
In reverse, the lower the frequency, the higher penetrance, but with a low-quality 
image. Therefore, the use of appropriate probe frequencies is required for an 
optimal US evaluation. The higher frequency transducers (e.g. 10–18 MHz) are 
mandatory for superficial structures, such as small joints of the hands and feet and 
ligaments and tendons, whereas lower frequency probes (e.g. 5–12 MHz) are useful 
for deeper joints, such as hip, knee or shoulder [90].
For most of the joints, US allows visualization of most features of rheumatoid 
arthritis, including joint effusion, synovial hypertrophy, bursitis, tenosynovitis or 
bone erosions, being more sensitive than clinical examination for depicting subclin-
ical synovitis and other inflammatory (Figure 2), acute changes and more sensitive 
than CR for detection of bony structural changes, like erosions [93, 94].
The outcome measurement in the rheumatology group (OMERACT), under the 
EULAR umbrella, developed definitions for all the US findings in rheumatology, 
which should be confirmed in two perpendicular planes. Thus, effusion is defined 
as abnormal hypoechoic or anechoic intraarticular material, that can be displaced 
and compressed, with no Doppler signal, whereas synovial hypertrophy or prolifer-
ation is defined as abnormal hypoechoic intraarticular tissue that is not displaceable 
and compressible but may exhibit Doppler signal [95].
Other inflammatory, acute, feature of RA is tenosynovitis, identified by the US 
as hypoechoic or anechoic thickened tissue with or without fluid within the tendon 
sheath, which is seen in two perpendicular planes and which may exhibit Doppler 
signal (Figure 3) [95].
Figure 2. 
US images showing - synovitis of MCP joint (asterisk – synovitis, mh – metacarpal head, f – phalanx, et – 
extensor tendon). Original image, from the personal archive (FLORIN VREJU).
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4.1 Original image, from personal archive (FLORIN VREJU)
Since the US is more and more used in daily practice both for diagnosis and 
monitoring disease, a scoring system for synovitis became mandatory. The most 
used is the one proposed by Szkudlarek et al. [96] that scored fluid as follows: grade 
0 – no effusion, grade 1 – minimal amount of fluid, grade 2 – moderate (no disten-
sion of the joint capsule) and grade 3 – extensive fluid collection (with distension 
of the joint capsule). The synovial hypertrophy was scored as grade 0 – none, grade 
1 – minimal synovial thickening, grade 2 – synovial thickening bulging over the line 
linking top of bone cortical (no extension along bone diaphysis), grade 3 – synovial 
thickening bulging over the line, with extension to at list one of the bone diaphysis. 
Semiquantitative grading included grade 0 – no flow, grade 1 – single vessel signal, 
grade 2 – Doppler signal in less than half of the area of synovium and grade 3 – 
Doppler signal over more than half of the synovial area (Figure 4). Recently was 
developed a new combined score, Global OMERACT – EULAR Sonography Scoring 
(GLOESS), which considered the higher score of GS or power Doppler (PD) as the 
score for the joint [97].
The most characteristic US finding in RA is bone erosion, defined as an intraar-
ticular step-down discontinuity of the bone surface that is visible in two perpendic-
ular planes [95]. Scoring system for erosions according to Szkudlarek et al. defined 
grade 0 as normal bone cortical, grade 1 as bone irregularities, but without defect in 
two perpendicular planes, grade 2 – the defect is seen in two perpendicular planes, 
grade 3 – extensive bone destruction [96]. A more accurate grading score for ero-
sions was the one based on irregularity size: grade 0 – no erosions, grade 1 – erosion 
<1 mm, grade 2 – small erosion between 1 and 1.9 mm, grade 3 – moderate erosion, 
between 2 and 4 mm, grade 4 – dimensions higher than 4 mm [98].
Validity of the method and sensitivity to change were primarily demonstrated 
for all US findings by Terslev et al. [99, 100], thus making it an important imag-
ing method in the management of RA, along with other studies which confirmed 
predicting value in the treatment response [101, 102], and the role in discriminating 
between clinical and imaging, real remission [93, 103, 104].
However, even if the diagnosis is enhanced and not made only by the US and 
even if it is highly operator dependent, ultrasonography offers a cheap and dynamic 
possibility for monitoring the disease activity and progression and for assessing the 
persistence of subclinical inflammation in RA [92, 93].
Magnetic resonance imaging represents a favored and favorite imaging method 
in inflammatory joint diseases, as it allows evaluation of all the structures involved 
in those pathologies, being able to depict synovitis, tenosynovitis, erosions and 
more than this, the bone marrow edema, a feature that remains hidden to the 
Figure 3. 
US images showing - tenosynovitis of the tibialis posterior (asterisk – tenosynovitis) in transverse, with Doppler 
activity (A) and longitudinal scan (B).
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US. MRI sequences that can be useful in RA patients include T1-weighted (T1w), 
favored by short imaging times and good anatomical details, T2-weighted (T2w) 
and short tau inversion recovery (STIR), both good for depicting inflammation, 
such as bone marrow edema or synovitis [105]. Adding intravenous contrast agent, 
like paramagnetic gadolinium (Gd) to T1w sequences allows us to visualize detailed 
structural lesions and, at the same time, the tissue vascularity and perfusion, 
inflamed synovium being easily recognizable. It is always advisable to use two 
sequences in parallel, to compare high signals in the water-sensitive (WS) one (T2w 
or STIR) with high-resolution details in the fat sensitive one (T1w). Thus, one can 
identify active erosions, by a hyperintense signal in WS sequences and hypointense 
signals in the T1w image [105].
As a conclusion, MRI allows identification of synovitis, tenosynovitis, and 
erosions and proves to be an important tool in the diagnosis, in the disease activity 
monitoring and treatment response. However, even if it brings complete informa-
tion on the peripheral joints, the use of MRI in RA patients in clinical practice 
remains lower in comparison to US and CR, due to issues related to availability, cost, 
and duration of an examination. More than this, it cannot offer a dynamic assess-
ment of structures [77].
5. Rheumatoid arthritis: pharmacotherapy
According to guidelines, the therapeutic approach for RA patients includes 
an early start of conventional synthetic disease-modifying antirheumatic drugs 
(csDMARDs), followed by biologic DMARDs (bDMARDs) and targeted synthetic 
DMARDs, aimed at a low disease activity or remission.
Regarding csDMARDs, Methotrexate (MTX) remains the first therapeutic 
choice, due to its immunomodulatory and immunosuppressive action, efficacy and 
sustained effect; it is administered orally or subcutaneous, with doses starting from 
7.5–10 mg weekly up to 20–25 mg/week, In case of MTX intolerance, leflunomide 
(10/20 mg/day) or sulfasalazine (2–3 g/day) should be considered as therapeutic 
agents [106]. Treatment monitoring requires CBC, ALT, AST and creatinine evalu-
ation at baseline, every 2–4 weeks for the first 3 months, every 8–12 weeks for the 
next 3–6 months and every 12 weeks after. Screening for hepatitis B and C should 
be performed before initiating the treatment. An increase over three times of 
hepatic enzymes requires treatment interruption [106].
If the therapeutic target is not achieved with csDMARD therapy, bDMARDs or 
tsDMARDs should represent the next approach (Figure 5) [106].
Figure 4. 
US images showing - tenosynovitis of flexor carpi ulnaris and wrist synovitis, with Doppler signal present 
(asterisk – tenosynovitis, fcu – flexor carpi ulnaris, # – wrist synovitis).
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5.1 Biologic agents
Rheumatoid inflammation is initiated and maintained through immunological 
pathways when activated T and B cells produce cytotoxins – directly toxic to tis-
sues – and cytokines such as TNF and interleukins (IL-1 and IL-6) – which provide 
further amplifies the interaction between pro-inflammatory cells [107, 108]. 
Biologic bDMARDs are licensed for the treatment of moderate-to-severe RA and 
target specific T and B-cell activation by [107, 109]:
1. Inhibiting TNF (with excessive production in the synovial fluid in RA) and 
reducing the progression of joint damage:
• Adalimumab,
• Certolizumab,
• Etanercept,
Figure 5. 
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-
modifying antirheumatic drugs [106].
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• Golimumab,
• Infliximab
2. Binding of the CD80/86 receptor and preventing co-stimulation interaction 
between T cells:
• Abatacept
3. Blocking the IL-1 receptor:
• Anakinra
4. Blocking the IL-6 receptor and presenting a better safety profile:
• Tocilizumab
5. Producing B-cell depletion and reducing the accumulation of bone damaging 
oxygen-free radicals:
• Rituximab
Early use of bDMARDs can improve patient outcomes, reduce the symptoms of 
RA and modify the course of the disease, leading to remissions that can last several 
years [110].
Biosimilars are highly similar molecules with equivalent therapeutic effect to 
bDMARDs, also prescribed in RA, to reduce treatment costs because they are authorized 
by comparing randomized controlled trial data [109]. Biologic agents may be effective 
when DMARDs therapy fails to bring improvement of the physical function, but they 
present higher costs due to their complex manufacturing process [107, 109]. Biologic 
agents are genetically derived from living human or animal cells as whole monoclonal 
antibodies or as a specific fragment of an antibody called fusion protein [109].
Therefore, their protein structure predisposes patients to increased risk for infection, 
reactivation of latent tuberculosis, development of lupus-type reaction (mostly charac-
terized by rashes, leukopenia, and thrombocytopenia) and vasculitis [107, 109, 111].
Pre-existing airway disease and interstitial lung disease have shown worsening 
symptoms and increased mortality after administering biological RA  treatment [111].
Therapy monitoring: all patients should perform tuberculin skin testing or 
interferon-gamma release assay (IGRA) blood test before commencing anti-rheumatic 
treatment with biologic agents. Pre-existing airway disease and interstitial lung disease 
have shown worsening symptoms and increased mortality after administering biologi-
cal RA treatment [110]. Neurological complications similar to multiple sclerosis symp-
toms and demyelinating disorders have also been associated with bDMARDs treatment 
and regular monitoring for new skin cancer is necessary regarding all patients receiving 
biologic agents [111]. Patients should not receive live vaccines during treatment, except 
for pneumococcal, influenza and hepatitis B which are killed vaccines [107, 109, 112]. 
Neurological complications similar to multiple sclerosis symptoms and demyelinating 
disorders have also been associated with bDMARDs treatment and regular monitoring 
for new skin cancer is necessary regarding all patients receiving biologic agents.
The bDMARDs have different pharmacokinetics properties and dosage, but sim-
ilar adverse reactions and contraindications for the TNF inhibitors (TNFi). All TNFi 
increases cardiac mortality in RA patients with associated congestive heart failure 
(class III/IV and an ejection fraction of 50% or less) [107, 109]. Lymphoproliferative 
cancers, especially in children and adolescents, have been reported after using 
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TNFi, therefore the US Food and Drug Administration (FDA) added a black box 
warning product labeling. Patients are recommended to use appropriate skin pro-
tection. TNFi does not increase the risk of congenital malformation and is classified 
as pregnancy category B (no documented human toxicity) [110, 113]. However, due 
to the intense placental transfer of Ig in the third trimester, TNFi may increase the 
risk of neonatal bacterial and fungal infections. The lowest risk appears in etaner-
cept and certolizumab, which are preferred for administration [113].
All in all, the following screening tests should be performed before initiating 
bDMARDs therapy:
1. Full infection history and screen, chest radiographs, tuberculin skin test, 
IGRA, asses risk factors for HIV, hepatitis B and C screening to exclude the 
presence of bacterial or viral infection;
2. Full blood count, urinalysis;
3. Check vaccination status;
4. Check the family/patient history of demyelinating disease or malignancy;
5. Review cardiac function;
6. Antibody profile assessment: anti-nuclear antibodies (ANA) and deoxyribo-
nucleic acid (DNA).
5.1.1 Adalimumab
Adalimumab is a TNFi, fully humanized IgG1 monoclonal antibody (MAb), 
with a lower risk than animal-derived agents of generating immune responses such 
as injection-site reactions to anaphylaxis. It neutralizes the biological function of 
TNF, therefore it is recommended in patients with moderate-to-severe active RA, in 
association with methotrexate (MTX), as 40 mg subcutaneous injection or as mono-
therapy, with a 40 mg increase dosage once a week if the patient presents low rates 
of disease response. Pharmacokinetic properties: the average absolute bioavailability 
following a single 40 mg dose was 64%, with a terminal phase half-life of approxi-
mately 2 weeks. Pharmaceutical forms: premixed syringes or injection pens contain-
ing 40 mg, which is administered every 14 days. Therapy monitoring and specific 
screening commune to all bDMARDS: during treatment and 6 months after stopping. 
Concomitant administration of adalimumab with other bDMARDs (etanercept, 
anakinra, abatacept) is not recommended based upon the increased risk for infec-
tions and other potential pharmacological interactions. FKB327, a biosimilar agent, 
presented pharmacokinetic equivalence and similar pharmacodynamic properties 
to adalimumab, with minor differences due to formulation buffers, but not clinically 
relevant [109, 114, 115]. To highlight their safety of administration in patients with 
RA, biosimilars are mentioned as highly similar molecules with equivalent therapeu-
tic effect to bDMARDs [109]. Biosimilars are prescribed to reduce treatment costs 
because they are authorized by comparing randomized controlled trial data [109].
5.1.2 Etanercept
Etanercept is a recombinant human soluble TNF-α receptor, produced in 
Chinese hamster ovary cells. It was the first TNFi approved by FDA in November 
1998 as an immune-suppressant for RA treatment. Other indications for 
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etanercept are: juvenile idiopathic arthritis, spondyloarthritis, and plaque pso-
riasis. Pharmacokinetic properties: slow absorption and elimination, bioavail-
ability 76%, the long half-life of 70 hours, and the presence of renal or hepatic 
impairment should not require dosage modification. Dosage: subcutaneous 
injection, 25 mg twice weekly or 50 mg once weekly. In 2018, its first biosimilar 
SB-4 also received approval and was developed as a single-use pre-filled syringe 
available at 25 and 50 mg. SB-4 lacks l-arginine and latex in the needle shield, 
which may explain the lower risk of injection site reactions in SB-4 treated 
patients. The most common adverse events are upper respiratory tract infections, 
nasopharyngitis, and hepatobiliary disorders. Neurological events have rarely 
been reported [109, 116, 117].
5.1.3 Golimumab
Golimumab, another human MAb, prevents TNF-α binding to its receptors, 
and it must be administered in combination with MTX in case of failure or intoler-
ance to other TNFi. Pharmacokinetic properties: absolute bioavailability 77%, the 
terminal half-life of 18 days, passage through placenta and breast milk. Dosage: 
the starting recommended dosage is 50 mg monthly, by subcutaneous injection, 
with a visible clinical response after 12–14 weeks of treatment. Treatment should 
be discontinued if no response appears after administering four doses of 100 mg. 
Precautions and adverse reactions are similar to other TNFi [107, 109, 118].
5.1.4 Certolizumab
Certolizumab pegol is a recombinant human MAb bound to polyethylene 
glycol which increases its half-life to approximately 14 days and reduces the risk 
of antibody-dependent cell-mediated cytotoxicity. It is indicated in associations 
with MTX for the treatment of moderate-to-severe RA in adult patients, with a 
recommended starting dose of 400 mg (as 2 subcutaneous injections of 200 mg 
each in 1 day) at weeks 0, 2 and 4, followed by 200 mg every 2 weeks as a main-
tenance dosage. Treatment should be discontinued if there is no response after 
12 weeks of treatment. Due to its reduced placental transfer, certolizumab is 
one of the safest biologic agents for use in pregnancy and can be given during all 
trimesters [107, 109, 113].
5.1.5 Infliximab
Adverse reactions are mostly observed in chimeric biologic agents, such as 
infliximab (which contain only 75% human antibodies), due to the development 
of neutralizing antibodies also associated with decreased therapeutic effect. 
Therefore, infliximab, a chimeric human-murine TNFi, which contains combined 
portions of mouse and human IgG1, must be administered with a low-oral-dose of 
MTX or prednisone to prevent adverse reactions. Dosage: it is the only monoclonal 
antibody administered only by intravenous infusion, at a dose of 3 mg/kg at weeks 
0, 2 and 6, and maintenance infusions at 8 weeks. A specific and acute infusion 
reaction presents as fever, pruritus, chills, and rash, after 2 hours of receiving the 
drug, however, anaphylactic shock rarely appears. Prior 30–60 minutes to inflix-
imab infusion, cetirizine 0.5 mg/kg or hydrocortisone 4 mg/kg and paracetamol 
15 mg/kg are necessary to avoid infusion reactions. Lupus-like-syndrome and 
vasculitis have also been reported. Blood tests should be performed to evaluate the 
eventual drop of infliximab plasmatic concentration which indicates the appearance 
of neutralizing antibodies [107–109].
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5.1.6 Abatacept
Abatacept is a fusion protein and a non-TNFi biologic medicine, which modu-
lates lymphocyte responses and inflammation by blocking a co-stimulatory signal 
for T-cell activity. It is always recommended to be used with MTX in highly active 
RA in patients without positive response in prior treatment with MTX or in patients 
who have a contraindication preventing them from receiving rituximab, another 
non-TNFi biologic agent. Pharmacokinetic properties: bioavailability 78%, the 
terminal half-life of 14 days, placental crossing, but no transfer through breast 
milk. Dosage: it can be administered as intravenous infusion depending on patient 
weight: 500 mg <60 kg, 750 mg <100 kg, 1000 mg > 100 kg, every 2 weeks for two 
initial doses and then every 4 weeks. Abatacept presents better persistence rates 
over TNFi, even though it is a second line biologic agent [119, 120]. Alternatively, 
it can be given by the subcutaneous injection of 125 mg once a week. Common 
adverse reactions include headaches, nasopharyngitis and upper respiratory tract 
infections, dizziness, back pain, hypertension, dyspepsia, urinary tract infections, 
rash. Several studies have shown that abatacept is associated with presents a better 
prognosis than other biologic agents in patients with RA and interstitial lung dis-
ease [111]. Precautions should nonetheless be taken in patients older than 65 years, 
due to the increased number of reported malignancy cases [107, 108].
5.1.7 Rituximab
Rituximab binds to CD20, a protein expressed on B lymphocytes and affects B and 
T-cell interaction and cytokine production, delaying bone and tissue damage. B-cell 
recovery takes several months, therefore rituximab has a prolonged effect which allows 
intermittent therapy based on the reactivation of arthritis symptoms. Dosage: clinical 
response is usually achieved within 16–24 weeks and both rituximab and its biosimilar 
are administered in association with MTX for better therapeutic outcomes. The first 
dose is 1000 mg by intravenous infusion followed by a second dose of 1000 mg after 
2 weeks, associated with intravenous methylprednisolone to prevent infusion reac-
tions. The risk of infusion reactions decreases after every administration. Paracetamol 
and antihistamines may also bring benefits to atopic patients. Rituximab is preferred to 
be administered to patients with a history of malignancies, due to the fact that ritux-
imab has not been associated with an increased risk of cancer. Contraindications for 
rituximab refer especially to severe active infections and severe heart failure [107, 109].
5.1.8 Tocilizumab
Tocilizumab binds to membrane receptors specific to IL-6 and therefore inhibits 
IL-6 which is involved in multiple regulation mechanisms of the immune response, 
hematopoiesis, and bone metabolism. In RA, IL-6 is responsible for raised platelet 
count, protein and auto-antibody overproduction, induction of osteoclasts, develop-
ment of inflammation and joint destruction. Tocilizumab is licensed as a treatment 
for RA, in association or not with MTX and in patients following other DMARDs 
failure or intolerance to them. It represents the only therapy that has shown superior-
ity over MTX monotherapy and other DMARDs, although the association with other 
antirheumatic drugs prolonged retention of tocilizumab [107, 109]. Furthermore, a 
retrospective observational study in 2019 has shown that tocilizumab and etanercept 
were the most persistent drugs, referring to retention rate and drug survival, with a 
median retention duration of 30.9 months. This study demonstrates a higher efficacy 
specific to tocilizumab [121]. Pharmacokinetic properties: half-life is maintained 
between 6 and 18 days, depending on concentration and administration rhythm. Due 
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to its mechanism of action, tocilizumab stimulates the action of cytochrome P450, 
especially CYP1A2, CYP2C9, CYP2C19, and CYP3A4, involved in the metabolism of 
many other drugs such as statins, warfarin, benzodiazepines, oral contraceptives, cal-
cium channel blockers, theophylline, phenytoin. Tocilizumab increases the need for 
a higher dosage if associated with these other classes of medicines. Patients receiving 
tocilizumab will present a reduction in plasmatic neutrophils and platelets, but also a 
growth in plasmatic lipid levels; treatment should not be initiated in patients with an 
absolute neutrophil count less than 2 × 109 L and patients should have their cholesterol 
levels checked 4–8 weeks after initiating treatment with tocilizumab [107, 109, 122]. 
Further cautions should be taken in patients with aminotransaminase levels greater 
than 1.5 times the upper limit. Dosage: it can be administered as a subcutaneous injec-
tion once a week with a dosage of 162 mg or as an intravenous infusion with a dosage 
of 8 mg/kg/every 4 weeks, with a maximum of 800 mg per infusion [107, 109, 122].
Supplementary precautions should be taken in pregnancy and administration of 
rituximab, tocilizumab, and abatacept, due to their limited safety documentation 
when compared with TNFi [113].
5.1.9 Anakinra
Anakinra is less effective than other biologics, therefore it is not normally recom-
mended, although patients with refractory disease can follow and benefit from this 
treatment. Failure of treatment in RA patients can be defined as a lack of response 
in 3 to 6 months after commencing therapy or as a loss of response after a first 
improvement was registered. Anakinra is a human IL-1 receptor antagonist, given 
as a subcutaneous injection in combination with weekly MTX. Dosage: 100 mg/per 
day, administered at approximately the same time each day. Topical glucocorticoids 
can avoid injectional reactions and are recommended. Specific adverse effects: 
rashes, urticaria, the elevation of hepatic enzyme levels, reproductive toxicity and a 
higher risk for serious infections and pulmonary events than other biologic agents, 
especially when associated with other TNF-antagonists [107, 109, 123].
5.2 Targeted synthetic DMARDs-JAK inhibitors (JAKi)
The multiple cytokines involved in the RA pathogenesis signal through Janus 
kinase/signal transduction and activator of transcription pathway (JAK-STAT). JAK 
represents intracellular tyrosine kinases associated with several cytokine receptors. 
JAK family includes JAK1, JAK2, JAK3, and TYK2 that are paired with specific recep-
tors. Depending on the structure of their receptors, cytokines can be classified in [124]:
1. Type 1 receptors:
• γ chain (IL-2, IL-7, IL-9, IL-15);
• gp 130 family (IL-6, IL-11, oncostatin M-OSM, leukemia inhibitory factor-LIF),
• p40 subunit (IL-12, IL-23)
• and β chain cytokines receptors (IL-3, IL-5, GM-CSF).
2. Type 2 receptors include IL-10 and TNF families.
Recently, RA therapeutic research has focused on intracellular pathways and 
with advances in technology and disease knowledge, more targeted therapies were 
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developed. JAKi represents an attractive therapeutic resource for patients with 
active moderate/severe RA, due to their oral bioavailability [124, 125].
Currently, there are two JAKi approved for RA treatment, associated with 
MTX or as monotherapy: tofacitinib (selective for JAK1 and JAK3) and baricitinib 
(selective for JAK1 and JAK2). Also, other agents are undergoing clinical studies: 
upadacitinib and filgotinib (selective for JAK1, 74-fold selectivity for the first agent 
and 28-fold for the second one), peficitinib (selective for JAK1 and JAK2) and 
decernotinib (JAK3 selective) [124–127].
5.2.1 Tofacitinib
Tofacitinib, the first oral JAKi approved for RA treatment, is a targeted small 
synthetic molecule, a reversible competitive inhibitor that binds to ATP bind-
ing site of the kinase domain of JAK. It selectively inhibits signaling through 
cytokine receptors associated with JAK3 and JAK1. Regarding its pharmacologic 
properties, it has a pharmacokinetic profile directly related to dose, with a half-
life of approximately 3 hours. It is metabolized by the liver, via cytochrome P450, 
primary, and cytochrome P2C19, secondary, and eliminated renal. It is recom-
mended for patients with moderate to severe RA, associated with MTX or in 
monotherapy, in doses of 5 mg twice a day [126]. Therapy monitoring: complete 
blood count should be performed at the initiation, 4–8 weeks after and every 
3 months afterward. Lipid profile should be evaluated 4–8 weeks after initiation 
and according to hyperlipidemia guidelines if it is the case. Liver enzymes should 
be periodically monitored. The recommendations for treatment interruption are 
presented in Table 1.
5.2.2 Baricitinib
As well as baricitinib, it should be used carefully in patients with risk factors 
for deep vein thrombosis (DVT) or pulmonary embolism (PE) (old age, obesity, 
history of DVT or PE, surgery or immobilization). It is not recommended in case 
of pregnancy, lactation or children; it is also important to administer with cau-
tion in patients over 75 years [127]. Baricitinib, the second agent approved for the 
treatment of RA is a competitive ATP kinase inhibitor, selective inhibitor of JAK1 
Monitoring Action
Lipid 4–8/12 weeks after treatment 
initiation and afterward according 
to hyperlipidemia guidelines
Management according to 
hyperlipidemia guidelines
Absolute neutrophil 
count (ANC)
Before initiation and afterward 
according to routine patient 
evaluation
Treatment interruption if ANC is  
<1 × 109cells/L; may be restarted once 
ANC is above this value
Absolute lymphocyte 
count (ALC)
Treatment interruption if ANC is 
<0.5 × 109cells/L; may be restarted 
once ANC is above this value
Hemoglobin (Hb) Treatment interruption if Hb is  
<8 g/dL and may be restarted once 
Hb is above this value
Hepatic 
aminotransferases
Temporary interruption if drug-
induced liver injury is suspected
Table 1. 
Monitoring tofacitinib and baricitinib treatment [128].
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and JAK2 (100-fold selectivity over JAK3), that reduces immune cell functions by 
targeting several cytokines (IL-6, IL-12, IL-23, IFNs, and GM-CSF) and growth 
factor stimulation. By presenting less affinity for JAK3 it may be associated with 
decreased immunosuppressive effects [128]. After oral administration is very fast 
absorbed, with a maximum plasmatic concentration of about 90 minutes and 
a half-life of 14 hours that allows once a day administration. It does not have a 
significant liver metabolization and is excreted in the urine, mostly unchanged. 
It is recommended to reduce the dose in case of renal insufficiency, for patients 
with a creatinine clearance between 30 and 60 mL/minute, and is contraindicated 
to be administered when the clearance is under 30 mL/minute. It is administered 
in doses of 4 mg/day. Doses of 2 mg/day should be considered for patients over 
75 years, with a history of infections or in case of persistent remission [129]. Safety 
and side effects: Before therapy initiation, all patients should be tested for latent 
tuberculosis and viral hepatitis and also baseline analyses must include absolute 
lymphocyte count (ALC), absolute neutrophil count (ANC) and hemoglobin. 
Laboratory changes that may be observed are represented by decreased hemoglo-
bin and neutrophils, increased hepatic enzymes, creatinine, low-density, and high-
density lipoprotein. Patients monitoring is presented in Table 1. During treatment, 
there were reported cases of tuberculosis reactivation, herpes zoster, malignancy 
and thrombosis [127].
5.2.3 Upadacitinib
Upadacitinib is an under investigation oral JAKi, with a higher selectivity for 
JAK1, which provided favorable efficacy, safety, and tolerability in the studies 
conducted so far. Similar to tofacitinib and baricitinib, demonstrated inhibition of 
radiographic progression in RA patients.
5.2.4 Figlotinib
Filgotinib presents a selectivity of almost 30-fold for JAK1 versus JAK2, with 
dose-dependent inhibition of Th1-Th2 [124, 130]. The most frequent side effects 
reported for JAK1 selective inhibitors are represented by nausea, cephalalgia, respi-
ratory and urinary infections, dose-related neutropenia and an increase in serum 
levels for creatinine and hepatic enzymes [127].
6. Conclusions
The extensive research of the last two decades has concerned the diagnosis and 
individual prognosis of patients with RA and also the elaboration of personal treat-
ment strategies.
Case management requires a continuous evaluation of the risk/benefit ratio of 
the therapy, so that the results are optimal and with minimal adverse effects and 
complications, including infections.
Also, anticipating a balance between the risks of comorbidities and the benefits 
of treatment is a management strategy that must be taken into account.
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